Patent: 10,139,399
Summary for Patent: 10,139,399
| Title: | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy |
| Abstract: | Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response during intravenous PEGylated uricase therapy in gout patients is provided. Routine SUA monitoring can be used to identify patients receiving PEGylated uricase who may no longer benefit from treatment and who are at greater risk for infusion reactions. |
| Inventor(s): | Theresa Rosario-Jansen, David Erick Wright |
| Assignee: | Horizon Therapeutics USA Inc |
| Application Number: | US15/906,839 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,139,399
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Horizon Therapeutics Ireland Dac | KRYSTEXXA | pegloticase | Injection | 125293 | September 14, 2010 | 10,139,399 | 2038-02-27 |
| Horizon Therapeutics Ireland Dac | KRYSTEXXA | pegloticase | Injection | 125293 | August 29, 2025 | 10,139,399 | 2038-02-27 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 10,139,399
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Australia | 2010265879 | ⤷ Start Trial |
| Australia | 2010265964 | ⤷ Start Trial |
| Brazil | PI1009732 | ⤷ Start Trial |
| Brazil | PI1010069 | ⤷ Start Trial |
| Canada | 2764761 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
